# Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

> **NCT06138028** · PHASE2,PHASE3 · RECRUITING · sponsor: **Qingdao Central Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Metastatic Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）

## Key facts

- **NCT ID:** NCT06138028
- **Lead sponsor:** Qingdao Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-20
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138028, "Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06138028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*